Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In the era of AI, omics and organoids, animal models are still needed in cardiovascular research.

Nature reviews. Cardiology·2026
Same author

Antithrombotic therapy for secondary prevention in patients with acute coronary syndromes treated with percutaneous coronary intervention: options for personalization to reduce bleeding or ischaemic risks. A Clinical Consensus Statement of the ESC Working Group on Thrombosis, the Association for Acute CardioVascular Care of the ESC, the European Association of Percutaneous Cardiovascular Interventions of the ESC, and the ESC Working Group on Cardiovascular Pharmacology A Clinical Consensus Statement of the ESC Working Group on Thrombosis, the Association for Acute CardioVascular Care of the ESC, the European Association of Percutaneous Cardiovascular Interventions of the ESC, and the ESC Working Group on Cardiovascular Pharmacology.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2026
Same author

Preclinical Evaluation of Berry Extracts as a Nutritional Intervention to Alleviate Myocardial Ischemia-Reperfusion Injury and Atherosclerosis Development.

Phytotherapy research : PTR·2026
Same author

Pathophysiology, prevention, and management of coronary microvascular obstruction.

European heart journal·2026
Same author

Subcutaneous Adipose Tissue as a Metabolic Mirror: Transcriptomic Insights Into Glycaemic Dysregulation.

European journal of clinical investigation·2026
Same author

Primed for metabolic syndrome: evidence of cardiac mitochondrial dysfunction preceding disease.

American journal of physiology. Heart and circulatory physiology·2026

Related Experiment Video

Updated: Jun 10, 2026

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

Nutraceuticals and atherosclerosis: human trials.

Lina Badimon1, Gemma Vilahur, Teresa Padro

  • 1Cardiovascular Research Center, CSIC-ICCC, Hospital de la Santa Creu i Sant Pau and IIB-Santpau, Barcelona, Spain. lbadimon@csic-iccc.org

Cardiovascular Therapeutics
|July 17, 2010
PubMed
Summary

Contemporary lifestyles contribute to obesity and cardiovascular disease (CVD). Nutritional strategies, including nutraceuticals, show promise in reducing atherosclerosis risk factors and promoting heart health.

More Related Videos

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

Inducing Myointimal Hyperplasia Versus Atherosclerosis in Mice: An Introduction of Two Valid Models
08:34

Inducing Myointimal Hyperplasia Versus Atherosclerosis in Mice: An Introduction of Two Valid Models

Published on: May 14, 2014

Related Experiment Videos

Last Updated: Jun 10, 2026

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

Inducing Myointimal Hyperplasia Versus Atherosclerosis in Mice: An Introduction of Two Valid Models
08:34

Inducing Myointimal Hyperplasia Versus Atherosclerosis in Mice: An Introduction of Two Valid Models

Published on: May 14, 2014

Area of Science:

  • Nutritional Science
  • Cardiovascular Medicine
  • Biochemistry

Background:

  • Sedentary lifestyles and diets high in saturated fats/sugars increase obesity, atherosclerosis, and cardiovascular disease (CVD) risk.
  • Epidemiological studies link high saturated/trans fat intake to elevated cholesterol and coronary heart disease (CHD) mortality.
  • Mediterranean diets, rich in fruits, vegetables, and fiber, are associated with reduced CVD risk.

Purpose of the Study:

  • To explore the role of nutritional interventions, particularly nutraceuticals, in managing atherosclerotic risk factors.
  • To review the evidence for beneficial cardiovascular effects of specific dietary components.
  • To highlight the need for further research into nutraceuticals' efficacy and interactions with medications.

Main Methods:

  • Review of epidemiological studies and clinical evidence on dietary components and cardiovascular health.
  • Analysis of research on nutraceuticals, including dietary fibers, omega-3 polyunsaturated fatty acids (PUFAs), antioxidants, and polyphenols.
  • Examination of the impact of monounsaturated fatty acids on gene expression related to atherosclerosis.

Main Results:

  • Positive cardiovascular effects are linked to dietary fibers, cholesterol-lowering agents, olive oil, omega-3 PUFAs, antioxidants, and polyphenols.
  • Monounsaturated fatty acids may modulate genes involved in atherosclerosis.
  • Some antioxidant trials have not confirmed atheroprotective effects, and interactions with medications require consideration.

Conclusions:

  • Nutraceuticals offer potential strategies for reducing atherosclerotic risk factors and improving cardiovascular health.
  • Further scientific evidence is needed to clarify the specific contributions of nutraceutical constituents to inhibiting atherosclerosis.
  • Understanding potential interactions between nutraceuticals and cardiovascular drugs is crucial for patient safety.